FibroGen (NASDAQ:FGEN) Issues Earnings Results

FibroGen (NASDAQ:FGEN) issued its quarterly earnings results on Tuesday. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.38) by $0.21, Zacks reports. The firm had revenue of $46.33 million for the quarter, compared to analyst estimates of $34.00 million. During the same quarter last year, the business posted ($0.52) earnings per share.

FibroGen Stock Performance

Shares of NASDAQ FGEN traded down $0.01 during mid-day trading on Wednesday, reaching $0.37. The company had a trading volume of 2,411,958 shares, compared to its average volume of 2,225,010. The company has a 50-day moving average price of $0.37 and a two-hundred day moving average price of $0.73. FibroGen has a 1-year low of $0.29 and a 1-year high of $2.93.

Analysts Set New Price Targets

Several equities research analysts have commented on the stock. William Blair reiterated a “market perform” rating on shares of FibroGen in a research report on Wednesday. StockNews.com began coverage on shares of FibroGen in a report on Wednesday, November 6th. They issued a “hold” rating on the stock.

About FibroGen

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.